Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
First pancreatic cancer vaccine approved
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Sep 16, 2014 15:04:47
The Ministry of Food and Safety (MOFS) approved Reavax for the treatment of pancreatic cancer.

Reavax, previously known as GV1001, is developed by KAEL-GemVax. It is used for metastatic pancreatic cancer patients who are not candidates for surgery due to aggressive tumors.

Reavax is made of fragments to the protein telomerase. It primes immune system cells to recognize telomerase by injecting small amounts in the vaccine.

The MOFS said, “ The efficacy of Reavax was not significant in the clinical trial conducted in UK, but it was proved that patients with high levels of eotaxin lived longer with Reavax. Reavax is approved for those patients only.”

KAEL GemVax should keep conducting its phase III clinical trial to confirm the efficacy for the patient group with high levels of eotaxin. It should register patients and properly trained physicians, report safety and efficacy of Reavax periodically and have patients agree on the terms before using it.

MOFD said, “It can be said Reavax is the 21st new drug developed by a Korean company as it completely acquired the patents and marketing rights and conducted clinical trials for commercialization.”
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com